MediciNova, Inc. stock is down 0% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 17.65% of the previous 17 December’s closed higher than November.
MediciNova, Inc. focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders. MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the. treatment of acute exacerbations of asthma, MN-001 (tipelukast) is an orally bioavailable small molecule compound to treat fibrotic diseases.